SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

Gainers

Wendy's (NASDAQ:WEN) shares increased by 16.3% to $7.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.1 billion.
Digital Currency X (NASDAQ:DCX) sharesread more...

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

Gainers

J-Star Hldg (NASDAQ:YMAT) stock increased by 5.2% to $2.02 during Thursday's after-market session. The company's market cap stands at $8.0 million.
Digital Currency X (NASDAQ:DCX) shares increased byread more...

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

Gainers

Digital Currency X (NASDAQ:DCX) stock rose 47.1% to $0.11 during Thursday's pre-market session. The market value of their outstanding shares is at $27.5 million.
Springview Holdings (NASDAQ:SPHL) stockread more...

Digital Currency X Technology Stock Plunges Friday: What's Happening?

Shares of Digital Currency X Technology are trading sharply lower Friday afternoon as investors react to a registered direct offering.read more...

Gainers

Kaixin Hldgs (NASDAQ:KXIN) shares rose 76.1% to $1.99 during Thursday's pre-market session. The market value of their outstanding shares is at $1.8 million.
Digital Currency X (NASDAQ:DCX) stock roseread more...

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

Gainers

Digital Currency X (NASDAQ:DCX) shares rose 8.6% to $0.63 during Tuesday's after-market session. The company's market cap stands at $200.9 million.
GMEX Robotics (NASDAQ:GMEX) stock moved upwards byread more...

DCX Unveils Ambitious Expansion Plan Beyond Digital Assets

Digital Currency X Technology (NASDAQ:DCX) is signaling another step in its strategic evolution, announcing a non-binding memorandum of understanding (MOU) with Whales AI Limited to explore bringing an AI-powered STEM robotics education platform to the United States and Canada. While the agreement remains subject to due diligence and definitive documentation, the proposed collaboration would significantly broaden DCX's business beyond digital asset infrastructure into one of the fastest-growing segments of the artificial intelligence market.

Digital Currency X Technology (DCX) Stock Rallies Over 31% After Hours: Here's What Is Going On

Digital Currency X shares jumped over 31% after hours following a $20 million AI education platform investment agreement.read more...

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

Gainers

Linkage Global (NASDAQ:UZX) stock increased by 9277.8% to $21.25 during Wednesday's after-market session. The market value of their outstanding shares is at $14.4 million.
Digital Currency X (NASDAQ:DCX)read more...

Gainers

Digital Currency X (NASDAQ:DCX) shares increased by 12.8% to $1.15 during Wednesday's pre-market session.
Beazer Homes USA (NYSE:BZH) stock moved upwards by 11.81% to $30.66. The company's market capread more...

Digital Currency X Technology, Inc. engages in the development, production, and sale of electric and gasoline vehicles. It specializes in the design and development, production, sales, after-sales service and export of new energy vehicles and vehicle parts. The company was founded by Hong Wei Mu, Jian Nong Zhang, Li Chun Wu, and Qing Jun Wang on June 14, 2022, and is headquartered in George Town, Cayman Islands.

Digital Currency X Technology Inc. - Ordinary Shares - Class A

Why Did DCX Slump Over 30% After-Hours Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The notice, dated Jan. 20, states that the company is not in compliance with rules that require a minimum closing bid price of $1.00 per share, the company said.&nbsp;</li><li>The company now intends to request an appeal of Nasdaq's decision by Jan. 27, failing which its securities are scheduled for delisting.</li><li>There is no assurance that the planned appeal will be successful, the company added.</li></ul> Shares of Digital Currency X Technology Inc. (DCX) slumped 32% after-hours on Friday after the digital asset treasury management company said that it received a written notice from Nasdaq that it is not in compliance with rules for sustained trading on the bourse.The notice, dated Jan. 20, states that the company is not in compliance with rules that require a minimum closing bid price of $1 per share, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/23/3225059/0/en/Digital-Currency-X-Technology-Inc-Announces-Receipt-of-Nasdaq-Delisting-Notification-Letter.html">said</a>.<h2 class="st-heading-2"> Plans Ahead</h2>The closing bid price for the company’s Class A ordinary shares has been below $1 per share over the past 30 consecutive days, the company noted.The company also noted that it is not eligible for time to demonstrate compliance as it effected a reverse stock split over the prior one-year period.The company now intends to request an appeal of Nasdaq's decision by Jan. 27, failing which its securities are scheduled for delisting and will be suspended at the opening of business on Jan. 29.Digital Currency X effected a 12-for-1 share consolidation with a market effective date of Jan. 22, 2026, in an effort to regain compliance with the minimum bid price requirement. However, it noted that it might not regain compliance with Nasdaq requirements. Further, there is no assurance that the planned appeal will be successful, it added.<h2 class="st-heading-2">Chijet To Digital Currency X</h2>Digital Currency was previously called Chijet Motor when it was still an automaker.However, in December, it announced a name change following an agreement with EdgeAI Frontier Technology Ltd. to acquire up to $1 billion in EdgeAI tokens at a 20% discount to prevailing market prices. The deal marked a pivot into decentralized intelligence and blockchain-enabled technologies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DCX stock rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levelsA Stocktwits user noted that while an appeal is planned, “as of now the ship is going down.”<stembedurl>https://www.stocktwits.com/premarketmaker/message/642744593</stembedurl>Another opined that the stock will indeed be delisted.<stembedurl>https://www.stocktwits.com/Nizou/message/642743677</stembedurl><a href="https://stocktwits.com/symbol/DCX">DCX stock</a> has lost nearly all its value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/autonomy-features-standard-on-tesla-after-discontinuation-of-autopilot/cmyRjkwR4W2">What Autonomy Features Come Standard On New Tesla Vehicle Purchases Now That Autopilot Is No More?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

The digital asset treasury management company said that it received a written notice from Nasdaq that it is not in compliance with rules for sustained trading on the bourse.

Chijet Motor Company Inc

Digital Currency X Technology Inc. Class A Ordinary Shares

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.18
Prev Close	$1.19
Open	$1.15
Dividend Yield	0.00%
50-Day Moving Average	$45.89
Beta	1.00
Avg. Volume	293,516.09
PE Ratio	0.00

52-Week High	$11,020.80
52-Week Low	$1.13
Market Capitalization	$2.79M
EPS (Annual)	-$247.35
Price to Book	0.00
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

DCX Fundamentals